Warrant Inducement

Theriva Biologics (TOVX) secured $4.0 million (potentially $4.4 million total) by incentivizing warrant exercises at $0.54. Investors receive new warrants for twice the shares exercised (up to 14,720,920 shares), exercisable post-stockholder approval and expiring in five years. Proceeds fund working capital. The deal provides immediate liquidity while shifting dilution risk to the future, contingent on shareholder approval and SEC registration for the new warrants. A.G.P./Alliance Global Partners advised on the transaction.

Healthcare Triangle (HCTI) unveiled a strategy to reshape its scale and capital, including acquiring Teyame.AI, a $34M revenue platform which doubles HCTI’s market cap. HCTI is marketing its QuantumNexis GenAI SaaS and exploring acquisitions like Niyama and Ezovion. A warrant inducement program lowered warrant strike prices to $2.00 and issued new warrants at $3.00. HCTI’s stock traded at $2.84 on October 13, 2025, up over 31% since September, driven by its strategic move to AI-driven patient engagement and data solutions.